Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$7.19 ▲ +0.34
(+4.96%)
MKT CAP: $739.9M • VOL: 1.38M
52W L $3 52W H $9
ROARABLE / RQD
D • 44/100
PIOTROSKI
2 / 9
ACHV // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $0 | $0 | $0 |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$54.6M | -$39.8M | -$29.8M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$49.5M | -$29.8M | -$24.5M |
| Capital Expenditures (CapEx) | $3.0K | — | — |
| Free Cash Flow (FCF) | -$49.5M | -$29.8M | -$24.5M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | — | — | — |
| Cash & Short-Term Equivalents | $20.9M | $12.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $21.5M | $20.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ACHV.